Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of chronic and genetic disease
3.2.1.2 Technological advancement in cell and gene therapy
3.2.1.3 Increasing investment in research & development activities
3.2.1.4 Expanded application in oncology and rare disease
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory challenges
3.2.2.2 High development cost
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Service, 2021-2032 ($ Million)
5.1 Key trends
5.2 Clinical trial design & planning
5.3 Supply & logistics services
5.4 Regulatory affairs & compliance
5.5 Data management & biostatistics
5.6 Site management & monitoring
5.7 Other services
Chapter 6 Market Estimates and Forecast, By Phase, 2021-2032 ($ Million)
6.1 Key trends
6.2 Phase I
6.3 Phase II
6.4 Phase III
6.5 Phase IV
Chapter 7 Market Estimates and Forecast, By Indication, 2021-2032 ($ Million)
7.1 Key trends
7.2 Oncology
7.3 Hematology
7.4 Endocrine/metabolic disorders
7.5 Infectious diseases
7.6 Neurology
7.7 Cardiovascular diseases
7.8 Musculoskeletal disorders
7.9 Other indications
Chapter 8 Market Estimates and Forecast, By Therapy Type, 2021-2032 ($ Million)
8.1 Key trends
8.2 Gene therapy
8.3 Cell therapy
8.4 Gene modified cell therapy
Chapter 9 Market Estimates and Forecast, By End-Use, 2021-2032 ($ Million)
9.1 Key trends
9.2 Pharmaceutical & biotechnology companies
9.3 Contract research organizations
9.4 Academic & research institutes
9.5 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2021-2032 ($ Million)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 ADVARRA
11.2 Charles River Laboratories International Inc.
11.3 Catalent Pharma
11.4 ICON PLC
11.5 IQVIA
11.6 Medpace, Inc.
11.7 Novotech
11.8 Precision Medicine Group, LLC
11.9 Parexel International
11.10 Syneos Health
11.11 Sharp Services, LLC
11.12 Thermo Fisher Scientific Inc.
11.13 Worldwide Clinical Trials
